Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kwan, Hiu Yee ^a   Niu, Xuyan ^b   Dai, Wenlin ^a   Tong, Tiejun ^a   Chao, Xiaojuan ^a   Su, Tao ^a   Chan, Chi Leung ^a   Lee, Kim Chung ^c,f   Fu, Xiuqiong ^a   Yi, Hua ^d   Yu, Hua ^a   Li, Ting ^a   Tse, Anfernee Kai Wing ^a   Fong, Wang Fun ^a   Pan, Si Yuan ^e   Lu, Aiping ^a   Yu, Zhi Ling ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c School of Continuous Professional Education Hong Kong   (Hong Kong)

^d GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^e BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOCTANE DERIVATIVE; FATTY ACID; FATTY ACID SYNTHASE; LIGNAN; LIPID; PALMITIC ACID; POLYCYCLIC HYDROCARBON; SCHIZANDRIN B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR;

ANIMAL; BLOOD; COMPLICATION; DIET RESTRICTION; DISEASE MODEL; DRUG EFFECTS; GENETICS; LIPID DIET; LIPID METABOLISM; LIPOLYSIS; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; METABOLOMICS; MOUSE; NONALCOHOLIC FATTY LIVER;

ANIMALS; CYCLOOCTANES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FASTING; FATTY ACID SYNTHASES; FATTY ACIDS; LIGNANS; LIPID METABOLISM; LIPIDS; LIPOLYSIS; LIVER; LIVER CIRRHOSIS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MICE; NF-E2-RELATED FACTOR 2; NON-ALCOHOLIC FATTY LIVER DISEASE; PALMITIC ACID; POLYCYCLIC COMPOUNDS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924787555     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09114     Document Type: Article

References (60)

1. Angulo, P. et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30, 1356-1362 (1999).
2. Ratziu, V. & Poynard, T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44, 802-805 (2006).
3. LaBrecque, D. et al. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. World Gastroenterology Organization Global Guidelines [1-29] (World Gastroenterology Organisation, 2012).
4. Kashi, M. R. et al. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 28, 396-406 (2008).
5. Nair, S. et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20, 23-28 (2004).
6. Rizos, C. V. et al. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 8, 15-32 (2009).
7. Leamy, A. K. et al. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 52, 165-174 (2013).
8. Gentile, C. L. & Paqliassotti, M. J. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 19, 567-576 (2008).
9. Zhang, Y. et al. Palmitic and linoleic acids induce ER stress and apoptosis in hepatoma cells. Lipids Health Dis 11, 1 (2012).
10. Cazanave, S. C. & Gores, G. J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 5, 71-85 (2010).
11. Feldstein, A. E. et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 37-43 (2003).
12. Kuhajda, F. P. et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 91, 6379-83 (1994).
13. Kohjima, M. et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 20, 351-358 (2007).
14. Ameer, F. et al. De novo lipogenesis in health and disease. Metabolism 63, 895-902 (2014).
15. Puri, P. et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50, 1827-1838 (2009).
16. Panossian, A. et al. Synergy and Antagonism of Active Constituents of ADAPT-232 on Transcriptional Level of Metabolic Regulation of Isolated Neuroglial Cells. Front Neurosci 7, 16 (2013).
17. Pan, S. Y. et al. Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. J Pharm Pharmacol 60, 399-403 (2008).
18. Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005-2023 (2012).
19. Anderson, N. & Borlak, J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60, 311-357 (2008).
20. Kwan, H. Y. et al. Lipidomics identification of metabolic biomarkers in chemically induced hypertriglyceridemic mice. J Proteome Res 12, 1387-1398 (2013).
21. Pan, S. Y. et al. A novel experimental model of acute hypertriglyceridemia induced by schisandrin B. Eur J Pharmacology 537, 200-204 (2006).
22. Tan, Y. et al. Deciphering the differential toxic responses of Radix aconiti lateralis praeparata in healthy and hydrocortisone-pretreated rats based on serum metabolic profiles. J Proteome Res 12, 513-524 (2013).
23. Feldstein, A. E. et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40, 185-194 (2004).
24. Chu, J. H. et al. Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells. World J Gastroenterol 17, 2379-2388 (2011).
25. Lawler, J. F. Jr. et al. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem 273, 5053-5059 (1998).
26. Shimozono, R. et al. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol 84, 62-70 (2013).
27. Shin, S. M. et al. Role of the Nrf2-ARE pathway in liver diseases. Oxid Med Cell Longev 2013, 763257 (2013).
28. Yang, J. J. et al. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis. Cell Signal 26, 2381-2389 (2014).
29. Yeh, M. M. & Brunt, E. M. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 128, 837-847 (2007).
30. Kim, S. W. et al. Oleuropein prevents the progression of steatohepatitis to hepatic fibrosis induced by a high-fat diet in mice. Exp Mol Med 46, e92 (2014).
31. Wang, J. et al. BL153 partially prevents high-fat diet induced liver damage probably via inhibition of lipid accumulation, inflammation, and oxidative stress. Oxid Med Cell Longev 2014, 674690 (2014).
32. Comar, K. M. & Sterling, R. K. Review article: Drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 23, 207-215 (2006).
33. Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362, 1675-1685 (2010).
34. Li, Y. et al. Protective effects of extract fructus Schisandrae chinensis on hepatic injury in experimental hepatic fibrosis rats. Journal of Jilin University 40, 285-288 (2014).
35. IP, S. P. & Ko, K. M. The crucial antioxidant action of schisandrin B in protecting against carbon tetrachloride hepatotoxicity in mice: a comparative study with butylated hydroxytoluene. Biochem Pharmacol 52, 1687-1693 (1996).
36. Chiu, P. Y. et al. Schisandrin B Enhances Renal Mitochondrial Antioxidant Status, Functional and Structural Integrity, and Protects against Gentamicin-Induced Nephrotoxicity in Rats. Biol Pharm Bull 31, 602-605 (2008).
37. Liu, Z. et al. Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition. PLoS One 7, e40480 (2012).
38. Morgan, K. et al. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 20, 843-854 (2008).
39. Kohjima, M. et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 20, 351-358(2007).
40. Lin, J. et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120, 261-273 (2005).
41. Vallim, T. & Salter, A. M. Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 82, 211-218 (2010).
42. Wajchenberg, B. L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21, 697-738 (2000).
43. Kim, J. B. et al. Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain. Mol Cell Biol. 15, 2582-2588 (1995).
44. Foretz, M. et al. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol. 19, 3760-3768 (1999).
45. Pape, M. E. et al. Physiological regulation of acetyl-CoA carboxylase gene expression: effects of diet, diabetes, and lactation on acetyl-CoA carboxylase mRNA. Arch Biochem Biophys. 267, 104-109 (1988).
46. Katsurada, A. et al. Effects of nutrients and hormones on transcriptional and posttranscriptional regulation of acetyl-CoA carboxylase in rat liver. Eur J Biochem. 190, 435-441 (1990).
47. Jensen-Urstad Anne, P. L. & Semenkovich, C. F. Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger. Biochim Biophys Acta 1821, 747-753 (2012).
48. Pan, S. Y. et al. Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate. Naunyn-Schmied Arch Pharmacol 383, 585-591 (2011).
49. Nishikawa, S. et al. The effect of fasting on hepatic lipid accumulation and transcriptional regulation of lipid metabolism differs between C57BL/6J and BALB/cA mice fed a high-fat diet. Toxicol Pathol 36, 850-857 (2008).
50. Li, R. Y. et al. Effect of short-term and long-term fasting on transcriptional regulation of metabolic genes in rat tissues. Biochem Biophys Res Commun 344, 562-570 (2006).
51. Amatruda, J. M. et al. [14C]palmitate uptake in isolated rat liver mitochondria: effects of fasting, diabetes mellitus, and inhibitors of carnitine acyltransferase. J Lipid Res 19, 688-694 (1978).
52. Checker, R. et al. Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-κB. Free Radic Biol Med. 53, 1421-1430 (2012).
53. Chiu, P. Y. et al. Schisandrin B stereoisomers protect against hypoxia/reoxygenation-induced apoptosis and associated changes in the Ca(2+)-induced mitochondrial permeability transition and mitochondrial membrane potential in AML12 hepatocytes. Phytother Res 23, 1592-1602 (2009).
54. Park, E. J. et al. Schisandrin B suppresses TGFβ1 signaling by inhibiting Smad2/3 and MAPK pathways. Biochem Pharmacol 83, 378-384 (2012).
55. Biesterfeld, S. et al. Frozen section diagnosis in donor liver biopsies: observer variation of semiquantitative and quantitative steatosis assessment. Virchows Arch 461, 177-183 (2012).
56. Letexier, D. et al. Comparison of the expression and activity of the lipogenic pathway in human and rat adipose tissue. J Lipid Res 44, 2127-2134 (2003).
57. Baqir, Y. A. & Booth, R. A new method for assaying rat liver microsomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and its application in a study of the effect of dietary cholesterol on this effect of dietary cholesterol on this enzyme. Biochem J 164, 501-508 (1977).
58. Seale, P. et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest 121, 96-105 (2011).
59. Ahmadian, M. et al. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metabolism 13, 739-748 (2011).
60. Jackel-Cram, C. et al. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol. 46, 999-1008 (2007).